News


All series


All News

Treatment with the immune checkpoint inhibitor nivolumab demonstrated dose-limiting toxicities when combined with the tyrosine kinase inhibitors sunitinib or pazopanib to treat advanced or metastatic renal cell carcinoma, according to the results of a phase I parallel cohort dose escalation trial. However, both combinations showed encouraging preliminary antitumor activity.

Patients with hydroxyurea resistant/intolerant polycythemia vera without palpable splenomegaly who were treated with ruxolitinib experienced a 3-fold increase in the likelihood of achieving hematocrit control over patients treated with physician’s-choice therapy, with a majority of those patients maintaining their response at 80 weeks, according to findings of a phase III prospective trial.

Olaparib has been approved by the FDA as a maintenance therapy for&nbsp;patients with deleterious or suspected deleterious germline or somatic <em>BRCA</em>-mutated advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to frontline platinum-based chemotherapy, as approved by an FDA-approved companion diagnostic assay.

During a presentation at the 2018 San Antonio Breast Cancer Symposium, data from a subgroup analysis of the phase III TAILORx trial demonstrated worse outcomes in African-American patients compared to Caucasian patients with early breast cancer following adjuvant therapy. Both groups had a similar risk of recurrence and had received similar types of therapy, according the report.

Harry P. Erba, MD, PhD, recently talked about the treatment considerations and decisions he makes when treating patients with primary myelofibrosis and polycythemia vera. Erba explained his treatment decisions for patients with myeloproliferative neoplasms based on 2 case scenarios to a group during a <em>Targeted Oncology </em>live case-based peer perspectives presentation.

Danny Rischin, MD,&nbsp;discusses the potential of cemiplimab in patients with cervical cancer. The PD-1 inhibitor cemiplimab demonstrated antitumor activity and a tolerable safety profile as a monotherapy and in combination with&nbsp;hypofractionated radiotherapy for the treatment of&nbsp;patients with metastatic or recurrent cervical cancer.

Based on findings from the phase III ARIEL3 trial, the European Medicines Agency&rsquo;s Committee for Medicinal Products for Human Use has issued a positive opinion recommending an expanded approval for single-agent rucaparib as a maintenance treatment for&nbsp;adult patients with platinum-sensitive relapsed high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy.

The first in-human study of CAR T cells targeting the tyrosine kinase receptor ROR1&nbsp;in patients with solid tumors showed that the cells could be transferred into patients safely and expanded in vivo, according to findings from the ongoing phase I study presented at the 2018 San Antonio Breast Cancer Symposium.